Driver mutations, cancer, and detection methods
Mutation is the permanent change in the DNA sequence of a genome. Mutations can alter the function of encoded proteins with pathophysiological consequences. Driver mutations are a type of gene alteration that can cause dysregulated cell division and give a growth advantage, ultimately leading to tumor development and progression [1, 2] . Driver mutations are a hallmark of cancer. For example, mutations in BRCA1/2 genes are closely correlated with breast cancer risk [3] ; lung cancers bearing mutated EGFR respond to EGFR inhibitors [4, 5] ; and melanomas bearing mutated BRAF usually respond to BRAF inhibitors [6, 7] . As driver mutations are cancer biomarkers, they have been targeted in precision oncology, for cancer diagnosis, tailored therapy, and treatment response monitoring [8, 9] .
Molecular cancer diagnostics requires sensitive detection of driver mutations at a very low frequency in early stages of cancer, and accurate quantification of mutation frequency in a complex biological sample [10] . Although many methods have been developed for the detection of mutation [11, 12] , there are still limitations in terms of clinically availability, sensitivity, specificity, and efficiency. Currently, PCR-based amplification methods including allele-specific PCR and digital PCR are widely used to detect cancer gene mutation in the clinic setting. These technologies require expensive instrumentation, reagents, well-trained personnel and standardized laboratory protocols, and the results may be compromised by contamination [13, 14] . The next generation sequencing (NGS) technology is a most promising method for high throughput cancer genome profiling and residual disease detection. However, its inherent weakness such as long turnaround-time (usually several weeks), high cost, requirement of adequate tissue source of nucleic acids, sequencing library preparation, complex bioinformatics, currently hinders its successful implementation in clinical practice [15] [16] [17] . Development of novel strategies for the accurate detection of gene mutations, in particular point mutations (single-base changes) or single nucleotide polymorphism (SNP), is urgently needed [18] [19] [20] .
In this review, we describe two different single-molecule platforms, nanolock-nanopore [21] (Figure 1(a) ) and nanocross-nanopore [22, 23] biosensers (Figure 1(b) ) for the detection of point mutations. The test-bed of these studies is the BRAF V600E mutation, which occurs with high prevalence in several types of cancer and is the target of several drugs [24] . Accurate detection of this SNP could help physicians diagnose cancers earlier and treat them with individualized therapies. Using the two nanopore methods, we are able to directly 'read' single DNA molecules of the low frequency BRAF V600E allele against a background of the wild-type sequence, and quantify the mutation frequency in tumor tissues of cancer patients.
Nanolock-nanopore and nanocross-nanopore sensors for SNP detections
The sensing element is a nanopore, a 2-nm-wide protein channel that is provided by α-hemolysin embedded in a lipid membrane. A transmembrane voltage is applied to drive an ion current through the pore. When a target molecule in the solution passes through the nanopore, it changes the current in a characteristic manner, thus producing an electric signature that enables single molecule target detection. In the BRAF V600E detection, we used a DNA probe that can hybridize with both mutant and wild-type alleles to form the mutant•probe and wild-type•probe complexes. Powered by the electrophoretic potential of the device, both complexes can be captured by the nanopore and subsequently unzipped by this molecular machine. In order to selectively discriminate the mutant BRAF allele, we have constructed the mutation sequence-specific nanolock and nanocross motifs.
Nanolock is a class of inter-strand stabilizing chemical structures that is formed by binding of a ligand [25] [26] [27] [28] at specific base pairs. Fundamentally the nanolock exploits the concept of a stimuli-responsive nucleic acid [29] , in which the polymer's properties are altered in response to an environmental stimulus such as ligand binding. For detection of BRAF V600E [21] ( Figure 1(a) ), we designed a special probe that forms -T 'nanolock' [25, [30] [31] [32] [33] . In contrast, the wild-type•probe complex does not contain the T-T mismatch and thus cannot form the nanolock. Most importantly, due to the high stability of the nanolock, the mutant•probe unzipping process in the nanopore splits into two consecutive steps that can be resolved in the nanopore. In contrast, the unzipping of the wild-type•probe complex without the nanolock remains a transient, cooperative, one-step process. This mechanistic difference in the unzipping processes allows the locked mutant•probe complex to generate a distinct nanopore signature. The nanolock-produced unzipping signature functions as an 'electrical fingerprint', enabling discrimination of the mutant allele from the wild-type sequence. With the fingerprint, we are not only able to 'read' each mutant allele molecules, but also quantify the mutation frequency (mutation percentage) in a tumor tissue sample by measuring the occurrence of the nanolock signature.
We have also developed a separate approach that exploits sequence specific cross-linking with a reactive probe strand that covalently captures the mutant BRAF target sequence [22, 23] (Figure 1(b) ). In this 'nanocross' approach, a DNA abasic site, embedded in a specialized probe sequence, enables Figure 1 . Single-molecule detection of cancer driver mutation by using nanolock-nanapore and nanocross-nanopore sensors. (a) Nanolock-nanopore detection of the BRAF V600E mutant allele in tumor tissue DNA sample; (b) Nanocross-nanopore detection of the BRAF V600E mutant DNA sequence. In both methods, the noncovalent nanolock (a) or covalent nanocross (b) is constructed only on the mutant•probe DNA complex. Their special molecular configuration changes in the nanopore produce a unique ion current signature (current blockade marked by red solid triangle), which serves as a fingerprint of a single mutant DNA molecule. highly selective covalent cross-linking to adenine 1799 in the BRAF V600E mutant gene sequence [34] . Importantly, the cross-linked probe-target complex gives an unmistakable, long-lasting current block in the nanopore device [22, 23] . This current signature is easily distinguished from the shortduration blocks caused by uncross-linked target•probe complexes derived from the wild-type sequence. Accordingly, we showed that the fraction of T > A mutant sequence could be quantitatively determined within mixtures containing a high background of the wild-type allele [23] .
Advantages, improvement, and applications
The nanopore has been broadly investigated for various genetic [35] [36] [37] [38] [39] , epigenetic [40] [41] [42] [43] and proteomic [44] [45] [46] detection strategies [47] . Many excellent studies have demonstrated nanopore's single-nucleotide sensitivity [48] [49] [50] , and ability to detect single-nucleotide polymorphism [49, [51] [52] [53] . However, their applications in point mutation detection in clinical setting have not been explored. The nanopore-based next-generation sequencing technology is being developed [52, [54] [55] [56] [57] , but currently the sequencing accuracy (90%) remains impracticable for detecting cancer mutations at low frequencies [58] . By comparison, a great advantage of the nanolock-nanopore and nanocross-nanopore sensors is their high sensitivity. Due to the capability to discriminate each individual mutation DNA molecules captured by the nanopore, the sensor in principle can detect mutant alleles at very low frequency. For BRAF V600E, the sensor has been used to identify mutant alleles at 1% in the presence of wild-type DNA. This sensitivity, which can be further enhanced upon system improvement (see later), is superior to commercially available mutation detection methods such as polymerase chain reaction (PCR) and next generation sequencing (NGS) [21] . In addition to high sensitivity, both nanolock-and nanocross-nanopore sensors exhibit their own advantages. The non-covalent nanolock can be formed immediately upon addition of the ligand in the solution, therefore vastly decreasing the time for sample preparation prior to detection. By comparison, the formation of the covalent nanocross takes much longer time. However, the resulting long-lasting blockade is a unique signature for unmistakable discrimination of the mutant DNA. The nanocross signature can be easily terminated by reversing the voltage polarity (to release the cross-linked DNA duplex into the solution) to capture the next DNA duplex. In addition, due to the nanocross' long block duration, we can record the time-dependent capture of cross-linked duplexes in a device with multiple nanopores embedded in the membrane. The current trace for such an experiment is characterized by stepwise current drops corresponding to sequential capture of cross-linked duplexes from the test solution (Figure 1(b) , right current trace). Because the single-molecule capture rate is proportional to the concentration of cross-links in the cis solution and the number of nanopores in the membrane, the multi-channel method will not only vastly shorten the detection time, but also increase the sensitivity, making it useful in particular for detection at low mutant frequency.
To enable future clinical applications, we need improve the performance of both nanopore sensors, including applicability, throughput and sensitivity. First, the nanolock and nanocross toolbox must be expanded in order to target a broader spectrum of driver mutations in human cancers (e.g. mutations on KRAS and EGFR). Among various SNPs, T or A can be detected using the T-Hg 2+ -T nanolock and nanocross; C or G can be detected using the C-Ag + -C nanolock [25, [30] [31] [32] [33] 43] . In addition, many mismatch-specific chelating compounds [26, 27] and metallointercalators [28] with great base-pair selectivity can be utilized to construct mutationtargeted nanolocks. Similarly, additional cross-linking motifs will be developed for the covalent capture of various target sequences. Furthermore, because accurate clinical diagnostics requires simultaneous detection of multiple mutations rather than just one, we will develop methods such as 'nanopore barcoding' (exploiting a method we developed for multiple microRNA detection [42] ) for simultaneous detection of multiple biomarker mutations. Last, the analytical procedure in the current stage could be slow (low DNA capture rate) due to the low DNA concentrations. To enhance the detection efficiency, one solution is utilizing miniaturized nanopore system such as droplet nanopore [45] and nanopore chips [58] . The miniaturized device allows using very small volume (1 µl) of solution. Therefore the detection can be performed in pre-concentrated and enriched sample with highly elevated single molecule capture rate. Ultimately, it may be possible to realize amplification-free detection in a clinical setting.
Early cancer diagnostics demand detection of mutations at very low frequency. The nanocross-and nanolock-nanopore sensors ultimately may be sufficiently sensitive to execute this task (Figure 1(c) ). Since this single-molecule detection technology can determine if a DNA molecule is a mutant or wild-type, its false-positive and false-negative rates are both low. Ideally, observation of just one mutant DNA in a given time (e.g. 1 h) would immediately suggests the presence of that specific mutation in the sample. Longer detection time results in higher sensitivity, because the chance to capture a single mutant DNA molecule increases as the detection time increases. Therefore, the techniques, in essence, yield digital signals that are sensitive enough to perform 'yes/no binary diagnostics' of a cancer mutation, allowing doctors to quickly take appropriate clinical action.
Recent studies have demonstrated that circulating tumor DNA (ctDNA) fragments carry tumor specific sequence alterations even in the early stages of cancer [59] . Present in the cell-free fraction of blood 'liquid biopsy', ctDNA offers a noninvasive 'real-time' biomarker of the disease [59] [60] [61] . While clinical use of nanolock-and nanocross-nanopore sensors for ctDNA detection remains to be explored, the initial results offer a possibility for a new non-invasive way to assist cancer early diagnostics, potentially leading to improved patient survival and quality of life. The promise of commercially available portable nanopore devices means that this approach could facilitate the early diagnosis of disease in low-resource clinical environments.
Because these nanopore techniques can be used to accurately quantify the frequency of a particular mutation (Figure 1(c) ), the clinical investigator would be able to use it for monitoring the levels of cancer mutations in patients being treated with particular drugs or other interventions, i.e. monitoring the efficacy of a treatment by measuring changes in the presence of driver mutations before and after administration of a given drug or surgical procedure. This would greatly help doctors in assessing the efficacy of therapy on a patient-by-patient personalized basis.
In summary, the nanolock-and nanocross-nanopore sensors are emerging as a powerful technology with an ability to detect point mutations that occur at very low frequencies. By intuitively observing the unzipping kinetics between nanolock-bound mutated DNA molecules and wild-type molecules in a nanopore or the unmistakable long-duration current blocks associated with cross-links, we are able to differentiate the mutated and wild-type gene sequences. Therefore, this single-molecule-based technology has a potential to be used in cancer diagnostics, personalized medicine, and biomarker discovery.
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